Conditions: Relapsing Multiple Sclerosis Clinically Isolated Syndrome
Keywords: Relapsing multiple sclerosis Clinically isolated syndrome RMS CIS RebiSmart™ Rebif® Interferon beta-1a
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 106
Healthy volunteers: no

Brief summary:
This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Rebif
Intervention descriptions: intervention 1: Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.

Protocol document: